The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
Published version of a preprint
Abstract
Purpose: Small cell lung cancer (SCLC) is a highly malignant disease with poor prognosis, necessitating the need to develop new and efficient treatment modalities. PRIMA-1Met (p53-dependent reactivation of massive apoptosis), also known as APR-246, is a small molecule, which restores tumor suppressor function to mutant p53 and induces cancer cell death in various cancer types. Since p53 is mutated in more than 90% of SCLC, we investigated the ability of PRIMA-1Met to induce apoptosis and inhibit tumor growth in SCLC with different p53 mutations. Experimental Design: The therapeutic effect of PRIMA-1Met/APR-246 was studied in SCLC cells in vitro using cell viability assay, fluorescence-activated cell-sorting analysis, p53 knockdown studies, and Western blot analyses. The antitumor potential of PRIMA-1Met/APR-246 was further evaluated in two different SCLC xenograft models. Results: PRIMA-1Met/APR-246 efficiently inhibited the growth of the SCLC cell lines expressing mutant p53 in vitro and induced apoptosis, associated with increased fraction of cells with fragmented DNA, caspase-3 activation, PARP cleavage, Bax and Noxa upregulation and Bcl-2 downregulation in the cells. The growth suppressive effect of PRIMA-1Met/APR-246 was markedly reduced in SCLC cell lines transfected with p53 siRNA, supporting the role of mutant p53 in PRIMA-1Met/APR-246-induced cell death. Moreover, in vivo studies showed significant antitumor effects of PRIMA-1Met after i.v. injection in SCLC mouse models with no apparent toxicity. Conclusion: This study is the first to show the potential use of p53-reactivating molecules such as PRIMA-1Met/APR-246 for the treatment of SCLC. Clin Cancer Res; 17(9); 2830–41. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using small-cell lung cancer (SCLC) cell lines, Roza et al. demonstrated that APR-246 administration promoted apoptosis, suppressed tumor growth in vitro, and inhibited tumor growth in mice injected with SCLC cells in vivo.330”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [330]
In the citing paper
“inhibits the growth of p53 mutant tumors of various origins in combination with other anticancer drugs.390–396”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [390]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Self-citationPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Self-citationReactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
Self-citationLi, Y., Mao, Y., Brandt-Rauf, P. W., Williams, A. C., & Fine, R. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0206 · Cited by 57
Research works printed but not linked: 38
- Christensen, 2009, Specifically targeted gene therapy for small-cell lung cancer, Expert Rev Anticancer Ther, 9, 437, 10.1586/era.09.10 · DOI
- Cooper, 2006, Small cell lung cancer: treatment review, Respirology, 11, 241, 10.1111/j.1440-1843.2006.00850.x · DOI
- Lally, 2007, Small cell lung cancer: have we made any progress over the last 25 years?, Oncologist, 12, 1096, 10.1634/theoncologist.12-9-1096 · DOI · Paper page
- Viktorsson, 2005, The role of p53 in treatment responses of lung cancer, Biochem Biophys Res Commun, 331, 868, 10.1016/j.bbrc.2005.03.192 · DOI · Paper page
- Fuster, 2007, Classic and novel roles of p53: prospects for anticancer therapy, Trends Mol Med, 13, 192, 10.1016/j.molmed.2007.03.002 · DOI
- Chipuk, 2003, Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription, Cancer Cell, 4, 371, 10.1016/S1535-6108(03)00272-1 · DOI · Paper page
- Rodriguez-Salas, 2001, Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas, Lung Cancer, 34, 67, 10.1016/S0169-5002(01)00230-6 · doi:10.1016/s0169-5002(01)00230-6
- Fujiwara, 1994, Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene, Cancer Res, 54, 2287
- Rusch, 1995, Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer, Cancer Res, 55, 5038
- Adachi, 1996, Induction of apoptosis but not G1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma, Cell Growth Differ, 7, 879
- Nemunaitis, 2009, Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck, Clin Cancer Res, 15, 7719, 10.1158/1078-0432.CCR-09-1044 · DOI
- Bykov, 2002, Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database, Carcinogenesis, 23, 2011, 10.1093/carcin/23.12.2011 · DOI · Paper page
- Zache, 2008, PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53, Cell Oncol, 30, 411
- Bykov, 2003, Small molecules that reactivate mutant p53, Eur J Cancer, 39, 1828, 10.1016/S0959-8049(03)00454-4 · DOI
- Pedersen, 2003, Transcriptional gene expression profiling of small cell lung cancer cells, Cancer Res, 63, 1943
- Poulsen, 2008, A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells, Cancer Gene Ther, 15, 563, 10.1038/cgt.2008.24 · DOI
- Rehman, 2005, Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells, Breast Cancer Res, 7, R765, 10.1186/bcr1290 · DOI
- de Leij, 1985, Characterization of three new variant type cell lines derived from small cell carcinoma of the lung, Cancer Res, 45, 6024
- Bulte, 1993, Intracerebral and subcutaneous xenografts of human SCLC in the nude rat: comparison of monoclonal antibody localization and tumor infiltrating lymphocytes, J Neurooncol, 16, 11, 10.1007/BF01324829 · doi:10.1007/bf01324829
- Pettengill, 1980, Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung, Cancer, 45, 906, 10.1002/1097-0142(19800301)45:5<906::AID-CNCR2820450513>3.0.CO;2-H · doi:10.1002/1097-0142(19800301)45:5<906::aid-cncr2820450513>3.0.co;2-h
- Carney, 1985, Establishment and identification of small cell lung cancer cell lines having classic and variant features, Cancer Res, 45, 2913
- Bepler, 1987, Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines, J Cancer Res Clin Oncol, 113, 31, 10.1007/BF00389964 · doi:10.1007/bf00389964
- Berendsen, 1988, Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up, Cancer Res, 48, 6891
- Wurtzen, 2001, Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line, Int J Cancer, 93, 855, 10.1002/ijc.1417 · DOI
- Forbes, 2006, COSMIC 2005, Br J Cancer, 94, 318, 10.1038/sj.bjc.6602928 · DOI · Paper page
- Hayes, 1999, Comprehensive TP53-denaturing gradient gel electrophoresis mutation detection assay also applicable to archival paraffin-embedded tissue, Diagn Mol Pathol, 8, 2, 10.1097/00019606-199903000-00002 · DOI
- Hensel, 1991, Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer, Oncogene, 6, 1067
- Berglind, 2008, Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination, Cancer Biol Ther, 7, 699, 10.4161/cbt.7.5.5712 · DOI
- Nakamizo, 2008, Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis, Neuro Oncol, 10, 275, 10.1215/15228517-2008-015 · DOI
- Lambert, 2010, Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis, Oncogene, 29, 1329, 10.1038/onc.2009.425 · DOI
- Shmueli, 2004, Regulation of p53 by Mdm2: fate is in the numbers, Mol Cell, 13, 4, 10.1016/S1097-2765(03)00529-X · DOI
- Muller, 2004, Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures, J Biol Chem, 279, 48846, 10.1074/jbc.M407687200 · DOI
- King, 2001, Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53, EMBO J, 20, 6297, 10.1093/emboj/20.22.6297 · DOI · Paper page
- Haupt, 1995, Induction of apoptosis in HeLa cells by trans-activation-deficient p53, Genes Dev, 9, 2170, 10.1101/gad.9.17.2170 · DOI · Paper page
- Murray-Zmijewski, 2006, p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress, Cell Death Differ, 13, 962, 10.1038/sj.cdd.4401914 · DOI · Paper page
- Rokaeus, 2007, PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins, Oncogene, 26, 982, 10.1038/sj.onc.1209858 · DOI
- Daoud, 2006, PRIMA-1 Releases the p73 bound to mutant tumor suppressor p53 in breast cancer cells, Proc Am Assoc Cancer Res, 47
- Rokaeus, 2010, PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73, Oncogene, 29, 6442, 10.1038/onc.2010.382 · DOI
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 364
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
Metadata
- Authors
- Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M., & Poulsen, H. S.
- Venue
- Clinical Cancer Research
- Published
- 2011-05-01
- Volume
- 17
- Issue
- 9
- Pages
- 2830-2841
- ISSN
- 1078-0432
- 1557-3265
- Cited by
- 118
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-3168
- The paper
- Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M., & Poulsen, H. S. (2011). PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-3168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.